YZYBIO-B (02496): Updated data on the phase II study of M701 for malignant ascites will be presented at the 2024 ESMO-ASIA conference.

YZYBIO-B (02496) announced that the company has independently developed epithelial cell adhesion molecules and differentiation cluster 3 dual targets...

Zhitong FinanceDec 10, 2024 18:52

Youth Bio-B (02496) appoints Wen Zhicheng as a non-executive director.

Youcan Life Sciences -B (02496) announced that the above resolutions from the first to the second item were approved at the extraordinary shareholders' meeting...

Zhitong FinanceOct 22, 2024 17:36

Sudden Movement Spotlight | Biomedical Class B shares rose in the afternoon, LKYG-B up 30%, institutions bullish on sector further recovery space

Biomedical Class B shares rose in the afternoon, as of the time of publication, Lai Kai Medicine-B rose by 27.88%, to 7.89 Hong Kong dollars; YimingAngke-B rose by 17.91%, to 5.86 Hong Kong dollars; Yasheng Medicine-B rose by 5.74%, to 46.95 Hong Kong dollars.

Zhitong FinanceOct 17, 2024 14:04

Hong Kong stock announcement: New China Life Insurance (01336) announces profit joy, expecting a net profit attributable to the parent of 18.607 billion yuan to 20.515 billion yuan for the first three quarters, a year-on-year increase of 95% to 115%.

Livzon Pharma (01513): Injection of acetic acid pristinamycin microspheres is newly approved for the indication of 'endometriosis'...

Zhitong FinanceOct 8, 2024 23:03

sino biopharm's subsidiary signs exclusive licensing and cooperation agreement with Uzziel Biopharma.

Sino Biopharm (01177) announced that its subsidiary, China Grand Pharmaceutical Group Co., Ltd. ("China Grand Pharmaceutical"), has signed an exclusive license and cooperation agreement with Wuhan Youzhiyou Biopharmaceutical Co., Ltd. ("Youzhiyou Biopharm") for the development, registration, production, and commercialization of M701 developed by Youzhiyou Biopharm in the mainland China region. China Grand Pharmaceutical will make an upfront payment and R&D milestone payments to Youzhiyou Biopharm of approximately 0.315 billion RMB based on the progress of research and development, and will pay up to a maximum of 0.7 billion RMB.

Sina Hong Kong stocksOct 8, 2024 08:04

You Jiyou Biological-B (02496.HK) entered into a license and cooperation agreement with Charoen Pokphand on M701.

格隆汇October 8th丨You Zhongyou Bio-B (02496.HK) announced that on October 7, 2024, the company (as the licensor) and sino biopharm (01177.HK) subsidiary Zhengda Tianqing Pharmaceutical Group Co., Ltd. ("Zhengda Tianqing", as the licensee) entered into a license and cooperation agreement. According to this agreement, the company grants Zhengda Tianqing the exclusive, sublicensable license for the development, registration, production, and commercialization of the licensed products in the licensed territory and field. Under the license and cooperation agreement, the company grants Zhengda Tianqing the license to develop the licensed products in the licensed territory and field

Gelonghui FinanceOct 8, 2024 07:44